Clinical Trials Sponsored by Astellas Pharma GmbH

Total 1563 results

Ganymed Pharmaceuticals GmbH

Completed

Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) (OVAR)

Ovarian Cancer

Belgium, Germany
University of Luebeck
Astellas Pharma GmbH

Completed

Minimizing Immunosuppression in Old for Old Kidney Transplantation (ESP-CNI)

Kidney Transplantation

Germany
Ganymed Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer

Solid Tumors

Germany, Switzerland, Latvia, Bulgaria, Lithuania
Ganymed Pharmaceuticals GmbH

Completed

Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

Solid Tumors

Germany, Latvia
University Hospital, Bonn
Octapharma; Astellas Pharma GmbH

Unknown

Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis

Rasmussen Encephalitis

Germany
Medical University of Vienna
Astellas Pharma GmbH

Completed

Pain Thresholds Under High-dose Topical Capsaicin

Pain

Austria
Medical University of Vienna
Astellas Pharma GmbH

Completed

Topical Local Anaesthesia and Cooling During Capsaicin 8% Patch Application (LACCA)

Pain

Austria
Astellas Pharma S.A.S.

Completed

A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year (COBALT)

Liver Transplantation

France
Astellas Pharma S.A.S.

Completed

Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology (OLYMPE)

Antifungal Prophylaxis | Haemopathy

France
Astellas Pharma S.A.S.

Completed

A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®) (OPALE)

Renal Transplantation

France
Astellas Pharma S.A.S.

Completed

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE)

Clostridium Difficile Infection

France
Astellas Pharma s.r.o.

Completed

A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain

Post-operative Peripheral Neuropathic Pain

Czech Republic
Astellas Pharma China, Inc.

Completed

A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

Rheumatoid Arthritis (RA)

China, Korea, Republic of, Taiwan
Astellas Pharma Europe Ltd.

Active, not recruiting

Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Liver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine Transplantation

Belgium, Czechia, France, Germany, Italy, Poland, United Kingdom
Astellas Pharma China, Inc.

Active, not recruiting

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (China ARCHES)

Metastatic Hormone Sensitive Prostate Cancer

China
Astellas Pharma Europe Ltd.

Completed

A Survey About Trade-offs When Choosing Menopause Treatments

Moderate to Severe Vasomotor Symptoms

United Kingdom
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Europe Ltd.

Completed

A Survey About Hot Flashes in Women Going Through the Menopause

Vasomotor Symptoms | Menopause

United Kingdom
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome (T-OPTIMUM)

Minimal Change Nephrotic Syndrome (MCNS) | MCNS

Korea, Republic of
Astellas Pharma China, Inc.

Completed

Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients

Renal Transplant Recipients

China
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Europe B.V.

Completed

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

Healthy Volunteers

United States
Astellas Pharma Europe B.V.

Completed

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis (SERENITY)

Interstitial Cystitis | Bladder Pain Syndrome

Spain, Russian Federation, Belgium, Czechia, Germany, Hungary, Latvia, Netherlands, Poland, United Kingdom
Astellas Pharma Europe Ltd.

Completed

A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death

Prostate Cancer

Sweden
Astellas Pharma a/s

Completed

A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

Metastatic Castration Resistant Prostate Cancer

Sweden
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

Healthy Subjects | Type 2 Diabetes Mellitus (T2DM) | Chronic Kidney Disease (CKD) | Pharmacokinetics of ASP8232 | Pharmacodynamics of ASP8232

Bulgaria, Moldova, Republic of, Romania
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (VIDI)

Diabetes Mellitus | Diabetic Macular Edema

United States
Astellas Pharma Korea, Inc.

Terminated

A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients (APPLE)

Lupus Nephritis

Korea, Republic of
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects (Maple)

de Novo Liver Transplant Subjects

Korea, Republic of
Astellas Pharma Korea, Inc.

Completed

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

Type 2 Diabetes Mellitus

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs) (TREASURE)

Rheumatoid Arthritis

Korea, Republic of
Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

YM443 in Subjects With Functional Dyspepsia

Nausea | Indigestion

United States
Astellas Pharma Europe B.V.

Completed

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (Neptune II)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Poland, Slovakia, Belarus, Germany, Czechia
Astellas Pharma Europe B.V.

Completed

A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

Type 2 Diabetes Mellitus

Germany
Astellas Pharma Europe B.V.

Completed

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (Neptune)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Hungary, Russian Federation, Poland, Slovakia, Czech Republic, Belarus, Germany
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea

Nausea | Vomiting

Taiwan
Astellas Pharma Europe B.V.

Completed

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (Blossom)

Urinary Bladder, Overactive

Belgium, Czech Republic, Germany, Spain, Sweden, United Kingdom
Astellas Pharma Korea, Inc.

Terminated

A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen

Kidney Transplantation

Korea, Republic of
Astellas Pharma Europe B.V.

Completed

An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation

Advanced Prostate Carcinoma

Russian Federation
Astellas Pharma Europe Ltd.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Herpes Zoster | Herpes Genitalis

France
Astellas Pharma Europe B.V.

Completed

A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects

Healthy Volunteers

United Kingdom
Astellas Pharma International B.V.

Terminated

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) (NADIR)

Chronic Lymphocytic Leukaemia (CLL) | Indolent Non Hodgkin's Lymphoma (iNHL)

Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients

Liver Transplantation

Taiwan
Astellas Pharma Europe B.V.

Completed

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery (ONYX-3)

Venous Thromboembolism | Arthroplasty, Replacement, Hip

Denmark, Spain, United States, Austria, Colombia, Russian Federation, India, Italy, United Kingdom, Germany, Hungary, Estonia, Romania, South Africa, Israel, Poland, Sweden, Canada, Australia, Lithuania, Ukraine, Latvia, Finland, Brazil, Slovak... and more
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

Healthy Subjects

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Astellas Pharma Inc
Astellas Pharma China, Inc.

Terminated

A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients

Lupus Nephritis

China
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (SOLAR)

Overactive Bladder | Urinary Incontinence | Urge Incontinence

France, Belgium, Spain, Turkey, Australia, Russian Federation, Hungary, Italy, Netherlands, Poland, Czech Republic
Astellas Pharma Korea, Inc.

Completed

A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients (SINGLE)

Kidney Transplantation | Renal Transplantation | Stable Renal Recipients

Korea, Republic of

3

Subscribe